DOV
69
-4
NWL
50
-6
UNH
60
-3
GT
60
-2
LRCX
48
2
AON
52
-8
UPS
48
-2
AEE
60
-3
SPG
60
-3
PYPL
56
-6
SO
53
-4
ILMN
42
-3
GE
65
-6
ADSK
70
-4
DNB
82
-4
MSI
76
-3
EXC
53
12
CSX
62
-6
AAL
59
2
KHC
15
-2
DOV
69
-4
NWL
50
-6
UNH
60
-3
GT
60
-2
LRCX
48
2
AON
52
-8
UPS
48
-2
AEE
60
-3
SPG
60
-3
PYPL
56
-6
SO
53
-4
ILMN
42
-3
GE
65
-6
ADSK
70
-4
DNB
82
-4
MSI
76
-3
EXC
53
12
CSX
62
-6
AAL
59
2
KHC
15
-2
Financhill
Back

Avenue Therapeutics Quote, Financials, Valuation and Earnings

America's enemies are regrouping & it may sucker punch your savings

Click here to learn more.
Sell
11

ATXI
Avenue Therapeutics

Last Price:
1.88
Seasonality Move:
15.12%

7 Day Trial

ALL ACCESS PASS

$ 7

"This Changes Everything" - Trump Hands Millions Massive IRS Gift

Learn More Here

Avenue Therapeutics Price Quote

$1.88

Avenue Therapeutics Key Stats

Sell
11
Avenue Therapeutics (ATXI) is a Sell
Day range:
$1.80 - $1.99
52-week range:
$1.70 - $26.47
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
0.56%
Volume:
14K
Avg. volume:
65.7K
1-year change:
-87.41%
Market cap:
$2.7M
Revenue:
$0
EPS:
$-15.45

How Much Does Avenue Therapeutics Make?

Data Unavailable

Is Avenue Therapeutics Growing As A Company?

Data Unavailable

Avenue Therapeutics Stock Price Performance

What Is Avenue Therapeutics 52-Week High & Low?

Avenue Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Avenue Therapeutics?

Is Avenue Therapeutics Cash Flow Positive?

  • What Is ATXI Cash Flow From Operations?
    Cash flow from operations (TTM) is -$8.6M
  • What Is Avenue Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $12.9M
  • What Is Avenue Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $0

Avenue Therapeutics Return On Invested Capital

Data Unavailable

Avenue Therapeutics Earnings Date & Stock Price

Avenue Therapeutics Competitors

  • Who Are Avenue Therapeutics's Competitors?
    Below is a list of companies who compete with Avenue Therapeutics or are related in some way:
    • Checkpoint Therapeutics Inc (CKPT)
    • Journey Medical Corp (DERM)
    • Fortress Biotech Inc (FBIO)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Palatin Technologies Inc (PTN)

Avenue Therapeutics Dividend Yield

Avenue Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 0%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 0
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 12.00
Upside from Last Price: 538.3%

Major Shareholders

  • How many ATXI shares are owned by institutional investors?
    3.7M ATXI shares are owned by institutional investors
  • How many ATXI shares are owned by insiders?
    0 ATXI shares are owned by insiders